HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted drug resistance to track transmission of viral strains already resistant to ART is also critical. Unfortunately, drug resistance testing is still not readily accessible in resource limited settings, because genotyping is expensive and requires sophisticated laboratory and data management infrastructure. An open access genotypic drug resistance monitoring method to manage individuals and assess transmitted drug resistance is described. The method uses free open source software for the interpretation of drug resistance patterns and the generation of individual patient reports. The genotyping protocol has an amplification rate of greater than 95% for plasma samples with a viral load >1,000 HIV-1 RNA copies/ml. The sensitivity decreases significantly for viral loads <1,000 HIV-1 RNA copies/ml. The method described here was validated against a method of HIV-1 drug resistance testing approved by the United States Food and Drug Administration (FDA), the Viroseq genotyping method. Limitations of the method described here include the fact that it is not automated and that it also failed to amplify the circulating recombinant form CRF02_AG from a validation panel of samples, although it amplified subtypes A and B from the same panel.
Introduction
The HIV epidemic in southern Africa has been evolving rapidly 1 with a concomitant exponential increase in individuals on antiretroviral therapy (ART), especially in South Africa 2, 3 . As evidence on the epidemiologic impact of large scale treatment programs in reducing incidence 4 and increasing life expectancy in resource-limited settings (RLS) 5 continues to accumulate, efforts to increase ART coverage will be intensified. The evolution of guidelines towards the use of treatment as a prevention tool 6, 7 under the test and treat programs means that the absolute number of individuals on treatment will further increase. Large numbers of individuals will be on ART for longer periods of time as the average life expectancy of individuals on ART nears that of the HIV uninfected population 8 . The development and transmission of HIV drug resistance has always been considered a threat to the achievements of ART [9] [10] [11] [12] . Thus, there is a need for more rigorous surveillance and monitoring of drug resistance as more individuals are initiated onto ART.
Genotypic drug resistance testing (GRT) has been used successfully in developed countries, both for surveillance as well as monitoring of HIV-1 drug resistance in individuals receiving ART. In these settings, GRT has been integrated into the continuum of care for HIV-1 infected individuals. Most international guidelines recommend GRT for adult or pediatric patients failing ART (first-line and second-line)
. It is expected that some of these recommendations will be integrated over time into the national treatment and monitoring guidelines of the various countries in the region. Already, in the 2013 South African treatment guidelines there is now recommendation of GRT at time of second-line failure for adults and at time of first-or second-line PI-based regimen failure for children 30 .
It has been shown that incorporating GRT into treatment guidelines in South Africa would be potentially cost-neutral. Considering the cost of the second line regimen drugs which are relatively more expensive than the first line drugs, using GRT to identify patients who truly need to be switched to second line therapy will not result any additional cost to the program. In addition, GRT can also identify other reasons for failure, conserve treatment options and generate information about emerging resistance patterns 31 . Therefore, it is necessary to reduce the cost of drug resistance monitoring methods even further in order to improve access, quality of care and outcomes.
Here, we present a GRT method designed to use generic (open source) primers for reverse transcription, polymerase chain reaction (PCR) and sequencing (Table 1) , as well as mostly open source software for drug resistance interpretation. For clinical management, the protocol is complimented by a comprehensive review and reporting method with specialist interpretation of the laboratory drug resistance report with close adherence to the national treatment guidelines. The protocol is divided into four different components; 1) HIV Ribonucleic Acid (RNA) Extraction, 2) Reverse Transcription and Polymerase Chain Reaction (PCR) amplification of viral targets, 3) Sequencing and 4) Bioinformatics methods for analysis of chromatograms, alignment, curation and interpretation of sequence data.
Protocol

Ethylenediaminetetraacetic Acid (EDTA) Whole Blood Processing
Note: Blood can be processed immediately after collection of can be stored at 4 °C for no more than 24 hr.
1. Working in a biosafety cabinet, allow the EDTA whole blood sample to reach room temperature. 2. For each sample, label enough cryovials with the sample identification (ID), storage material (plasma), and date. 3. Centrifuge the samples for 10 min at 1,000 x g. Do not use brakes to stop centrifuge. This will yield three layers (from top to bottom): plasma, leucocytes (buffy coat) -a very thin layer -and erythrocytes, including platelets. 4. Carefully aspirate the supernatant (plasma) and aliquot 500 ml into each cryovial. Take care not to disrupt the cell layer (buffy coat) or transfer any cells. 5. Store at -80 °C until needed for RNA extraction or proceed to RNA extraction immediately.
RNA Extraction
1. Prepare an extraction worksheet with the IDs of the samples to be extracted including positive and negative plasma controls. 2. For each sample to be extracted, label a 1.5 ml sterile microcentrifuge tube with the sample ID, extraction date and "RNA". Also label an assembled column and collection tube as well as a 2 ml microcentrifuge tube containing working lysis solution with corresponding numbers from the extraction worksheet. 3. Working in the Bio-Safety Cabinet, add 200 µl sample to the corresponding 2 ml microcentrifuge tube of working lysis solution. 4. Vortex well and incubate for 10 min at room temperature. 5. After 10 min, centrifuge the tube briefly. 6. Add 800 ml of absolute ethanol to each of the tubes. 7. Mix by pulse vortexing and briefly centrifuge. 8. Transfer 600 µl of this solution to the corresponding column/collection tube assembly. Centrifuge at 6,000 x g for 1 min. 9. Transfer column to a new collection tube and discard the old collection tube containing the filtrate. Repeat the above step 2.8 (above) twice more. 10. Add 500 µl wash buffer AW1 to each column and centrifuge at 6,000 x g for 1 min. 11. Discard the filtrate and collection tube and transfer the column to a new collection tube. 12. Add 500 µl was buffer AW2 and centrifuge at 20,000 x g for 3 min. Repeat step 2.11. 13. Centrifuge in a new collection tube at 20,000 x g for an additional 2 min. 14. Discard filtrate and place column in 1.5 ml microcentrifuge tube. 15. Add 60 µl Buffer AVE (RNase free water) to the middle of the column ensuring that you do not dispense the liquid on the side of the column. 16. Incubate at room temperature for 1 min. 17. Centrifuge at 6,000 x g for 2 min. 18. Discard the column and cap the 1.5 ml microcentrifuge tubes. 19. The samples are now ready for reverse transcription. 20. If testing is to be performed immediately, store at 4 °C for up to 6 hr. However, if testing is to be delayed then place at -80 °C immediately. NB:
do not freeze/thaw the samples more than 3x.
Reagent Preparation for Reverse Transcription
1. Before starting, calculate the volumes of each of the reagents required for the number of samples being processed including, the positive and negative plasma controls. Also add a reagent control. 2. Using the calculated volumes from step 3.1 (above), prepare the deoxyribonucleotide triphosphate (dNTP)-primer mix in a clean, sterile 200 µl PCR tube followed by briefly pulse vortexing. Each sample should have 0.5 µl of the reverse primer RT21 and 0.5 µl of the dNTP, see Table 2 . 3. Aliquot 1.0 µl of the dNTP-primer mix to 200 µl PCR tubes.
Reverse Transcription
1. Add 6 µl of the RNA sample to the dNTP-primer mix tube followed by briefly vortexing to mix. 2. After the addition of the RNA, move to the PCR room with both dNTP/primer/RNA mix and RT Enzyme mix tubes on a cold block or ice. 3. Briefly centrifuge the dNTP/primer/RNA mix tubes (from step 4.2) and place them into a thermocycler. 4. Heat at 65 °C for 5 min to denature the RNA. 5. Rapidly cool to 4 °C, hold for 2 min. 6. Pause the thermocycler while still at 4 °C; take out the tubes. 7. Quickly add 5 µl of the enzyme mix while keeping the tubes on a cold block. 8. Mix gently by tapping the tube then briefly centrifuge the tubes and return to the thermocycler. 9. Hold the tubes at 50 °C for 60 min to reverse transcribe the RNA followed by enzyme denaturation at 85 °C for 5 min to stop the reverse transcription. 10. Cool to 37 °C. As soon the temperature gets to 37 °C, pause and take the tube out of the thermocycler. 11. Quickly add 0.5 µl of RNAse H to the tubes and return to the thermocycler. 12. Hold at 37 °C for 20 min and then cool to 4 °C. 13. The complementary DNA (cDNA) can be used immediately or can be stored at -20 °C or colder until needed. However, the long term storage of cDNA should be at -80 °C.
Reagent Preparation for PCR
1. Before starting, calculate the volumes of each of the reagents required for the number of samples being processed and the controls. In addition to the three controls (Positive, Negative, and Reagent), you can also add a PCR control (HIV DNA). The first and second round PCR mixes can be prepared simultaneously and the second master mix stored at -20 °C until needed. Mixes can be stored for approximately 8 hr. 
PCR Product Cleanup
1. In preparation for the sequencing reaction, the positive second round PCR products are cleaned up using the PureLink PCR purification kit. 2. Add 80 μl of working Binding buffer High-Cutoff (B3) to 20 µl of PCR product and pipette mix. 3. Add the sample mixed with the binding buffer to a spin column in a collection tube. 4. Centrifuge the column at 10,000 x g for 1 min. Transfer the column into a new collection tube. 5. Wash the column with 650 µl of Wash Buffer with ethanol. 6. Centrifuge the column at 10,000 x g for 1 min. Transfer the column into a new collection tube. 7. Centrifuge the column at maximum speed for 2-3 min to remove any residual wash buffer. 8. Place the spin column in a clean 1.7 ml elution tube supplied with the kit. 9. Add 40 µl of elution buffer to the center of the column and incubate the column at room temperature for 1 min. 10. Centrifuge the column at maximum speed for 2 min (>10,000 x g). 11. The elution tube contains your purified PCR product ready for sequencing. Discard the column. 12. Determine the concentration and quality of the DNA using a Nanodrop. 13. If no in-house sequencing facilities are available, the purified PCR products can be sent to a commercial sequencing lab at this stage.
Sequencing Reactions
1. The PCR products are sequenced using the big dye terminator kit version 3.1 and 4 primers for each sample (two forward and two reverse).
The primer sequences are shown in Table 2 . Therefore, after the sequencing run, each sample will have four sequences to be assembled into a contig. 2. Set up the sequencing reactions as indicated in Table 5 for each of the four primers.
1. Sequence Assembly 1. Launch the program Geneious. 2. Create a working folder to store the sequences. 3. Import the ABI files generated by the sequencing machine to the working folder using the import tool. Geneious will allocate percentage quality score for each sequence imported. 4. Open sequences with quality scores >70% by double clicking on them. 5. Each file should open in a new window. The software will indicate the quality at each nucleotide position of the chromatogram of the sequence quality using light blue bars. The higher the bar, the better the quality of the base call. 6. Using the cursor, select the mid section of the sequence leaving out the ends, which are usually of poor quality. 7. Click on the extract button to extract the region with good quality sequence. 8. Select all four extracted sequences for each sample and assemble them against a reference sequence. 9. Inspect the assembled sequence to ensure that you are in the correct reading frame. If you are in the correct reading frame, the beginning of Protease should start with the following amino acids: PQITLW. The beginning of RT will start with PISPIE. 10. Extract the contig region covering the beginning of PR to the 300th RT codon. During this process, also check for insertions or deletions. 11. Go through the consensus sequence of the extracted contig, identifying any ambiguities and verify positions with mixed bases by inspecting quality (symmetry, height, background and shoulders of flanking regions) of the base calls. 12. Select the consensus sequence and click the extract button to create a separate file of the consensus sequence from the four primers and label it appropriately. 13. Export the sequence to a backup storage folder on the computer or a network folder.
Sequence Quality Assessment (HIVDB)
1. Analyze the sequence using the HIVDB program at http://hivdb.stanford.edu. 2. Check for deletions and insertions in the summary data and ensure that the sequence covers all the 99 protease (PR) codons and the 1st 300 RT codons. 3. Check for any highlighted quality assurance (QA) issues in both the PR and RT regions, such as stop codons, frame shifts, ambiguous positions and unusual residues.
3. Sequencing Quality Control 1. Blast the new sequence against a local sequence database from previous run. 2. If the new sequence is >97% similar to any sequence in the database, all the stages of the protocol should be reviewed, starting with the sequence analysis and going back to the RNA extraction to ensure that there were no mix ups (sample switching, mislabeling) or contamination.
A panel of five samples was used to assess the precision of the in-house method. Ten replicate genotypes were generated for each of the five samples. Using the 16 Capillary 3130xl genetic analyzer, 48 of the 50 genotypes were generated from 24 runs, prepared on the same day. For all five samples, the predicted amino acid sequences were 100% concordant amongst replicates. For the nucleic acid sequences, there was >99% pairwise similarity.
During the first two years of the use of this method, sixty samples were repeated randomly from RNA extraction to sequencing. There were no statistically significant differences between the sequence quality score and the number of mixed bases between the replicates. Both the nucleotide and amino acid pairwise comparisons for the sixty pairs were greater than 99% identical. Thus the drug resistance mutations for all the pairs were 100% concordant.
Cost reduction
The reaction volumes for RT, PCR and sequencing were reduced by at least half, relative to the original method 20, 32 , without compromising on the quality of the sequences generated. This enabled a reduction in cost of 50% for the RT and PCR stages.
The new method was originally designed to work with six sequencing primer to sequence all 99 codons of the protease gene and the first 300 codons of the reverse transcriptase gene 20, 32 . Similar methods also use six to eight primers 33, 34 . Some recently published methods have used less than six primers, although sometimes sequencing the protease and RT genes seprately 35, 36 . We sought to reduce the number of sequencing primers from six to four, (Figure 6 Sequences from a set of 17 samples generated from six primers were compared to sequences generated after exclusion of two primers (MAW46 and RTY). The subtypes were 14 subtype C, two subtype B, and one subtype A. There were no significant differences in sequence quality scores. Again, the average pairwise identity between the 17 pairs of nucleic acid was 99% and 100% on the amino acid level. Thus, reducing the sequencing primers from six to four resulted in a reduction in the sequencing cost by almost a third.
The only proprietary software tool used in this protocol was Geneious for sequence assembly. The drug resistance interpretation tools, as well as the report generating tools are all free, open access tools. This reduces the cost further by eliminating the costs associated with the use of proprietary software. Further, collective negotiation allowed the reagents for this protocol to be packaged into a kit for easy access from Life Technologies and is available as the SATuRN/Life Technologies genotyping method 37 . Furthermore, SATuRN members can access the reagents at a discounted price.
Clinical Setting
The described protocol has been implemented in the monitoring and surveillance of drug resistance in a rural community in KwaZulu-Natal. A total of 604 genotypes were generated from clinical samples between December 2010 and May 2013 at an amplification rate of 95% for samples with viral loads >1,000 RNA copies/ml. This clinical HIV drug resistance study was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (ref. 
Discussion
Several low cost in-house methods have been described in efforts to try to make HIV drug resistance genotyping more affordable 33, 34, 36 . There is no doubt of the need to integrate drug resistance testing into the continuum of care for individuals on antiretroviral therapy in resource-limited settings. However, most of the reported methods focus on the application of drug resistance genotyping in the surveillance of drug resistance at a population level. The SATuRN/Life Technologies genotyping method is a fully integrated protocol for surveillance and monitoring of drug resistance. This method was designed to be an affordable protocol implementing mostly open source and open access bioinformatics resources for the interpretation of drug resistance and generation of reports for clinical management.
It was shown through comparison with the FDA approved Viroseq genotyping method to be accurate in identifying drug resistance mutations from a panel of ANRS proficiency testing samples, in 100% of laboratory panel samples that were successfully amplified. The accuracy was also assessed on clinical samples of subtype C viruses, the most dominant subtype in southern Africa. The method was as accurate on subtype C samples as it was on subtype A and B. However, if the method would be used in other parts of the world where CRF02_AG is prevalent, there is a need for the modification of the primers since the method failed to amplify one of the panel samples that was shown to have CRF02_AG. Alternatively, a degenerate set of primers sensitive to all group M viruses 33, 36 could be used in regions where the subtype distribution is more heterogeneous 38 .
The sensitivity of the reverse transcription and PCR can be increased by extracting RNA from higher volumes of plasma, such as 500 ml. The plasma can be centrifuged at 21,000 x g for 90 min to concentrate the viral particles before proceeding with the protocol as described by the QIAamp viral RNA extraction mini kit.
As shown, the new method has an additional advantage that it produces comprehensive reports for individual patient management. These reports are a consolidation of the genotype, the immunological and virologic monitoring data as well as clinical and treatment history from RegaDB. This is accompanied by a detailed laboratory interpretation of the resistance profile followed by an equally detailed review of the patient's clinical history as well as treatment recommendations. The use of a specialist physicians to review the reports and provide treatment recommendations for the patients provides the much-needed mentorship for nurse practitioners as well as inexperienced clinicians, who are increasingly providing ART in South Africa as part of the WHO recommendations for task shifting. These clinical reports have been shown to be effective teaching aids for clinicians with little or no experience in drug resistance management. From a patient perspective, our method reduces the need to travel to centralized sites to access specialist HIV services.
Thus, the described protocol taken as a whole provides a good platform through which HIV drug resistance management can be integrated, at an affordable cost, into the continuum of care for HIV infected individuals failing ART. The data generated can be used for epidemiological purposes to assess the evolution and transmission of drug resistance in the community. The size of the pol fragment generated is good enough for more complex phylogenetic analysis which will produce better understanding of the epidemic at population level.
